Cardio Diagnostics
Get Started
Hero Background

About Cardiovascular Disease

Cardiovascular Disease

A Crisis in Plain Sight

Cardiovascular disease (CVD) is the #1 cause of death in the U.S., responsible for nearly 1 in 3 deaths. Despite advancements in care, research, and prevention, CVD continues to outpace all other chronic diseases. CVD is not one condition; it's a family of diseases that affect the heart and blood vessels. This includes:

  • Coronary heart disease (CHD)
  • Heart attacks (myocardial infarction)
  • Stroke
  • Heart failure
  • Peripheral artery disease

About Coronary Heart Disease

CHD often develops silently over many years, and its first symptom may be a heart attack.

#2

cause of hospitalization and adds $13,000 more per year to patient healthcare costs,

1 in 20

U.S. adults aged over 20 years live with coronary heart disease

3-4 million

Americans are affected by Ischemia with No Obstructive Coronary Arteries (INOCA), a subset of CHD

About Heart Attacks

Heart attacks don't always announce themselves. Many occur without chest pain, especially in women and people with diabetes.

40 seconds

is how often someone in the U.S. experiences a heart attack

1 in 5

heart attacks are silent, occurring without warning

800,000+

is the number of heart attacks occurring annually

Current Tools Can Leave Gaps in Cardiovascular Care

Traditional risk models (e.g., age, cholesterol, blood pressure) offer one-size-fits-all guidance, while tools like CT scans and stress tests detect disease after symptoms appear. But both often miss the early, complex stages of coronary heart disease.

Early Detection

Individuals at high risk may not be identified early enough

Undetected

Others with active, asymptomatic disease may go undetected

High Risk

Some patients may be labeled high-risk without underlying disease

Intervening

Opportunities to intervene, before symptoms or events occur, can be missed

Our Tests Analyze Epigenetic and Genetic Biomarkers Reflective of Inherited Predisposition and Acquired Factors from Lifestyle and Environment

Explore Our Solutions
  1. Centers for Disease Control and Prevention. "Heart Disease Facts." Centers for Disease Control and Prevention. Accessed September 2, 2025. https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
  2. Haidar, A., et al. "National Costs for Cardiovascular-Related Hospitalizations and Inpatient Procedures in the United States, 2016–2021." American Journal of Cardiology 234 (2024): 63–70. https://doi.org/10.1016/j.amjcard.2024.10.003
  3. Kazi, D. S., M. S. V. Elkind, A. Deutsch, et al. "Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050." Circulation 150, no. 4 (2024): e89–e101. https://doi.org/10.1161/CIR.0000000000001258
  4. Tsao, C. W., A. W. Aday, Z. I. Almarzooq, et al. "Heart Disease and Stroke Statistics—2023 Update." Circulation 147 (2023): e93–e621. https://doi.org/10.1161/CIR.0000000000001123
  5. Polyak, A., J. Wei, M. Gulati, and N. Bairey Merz. "Clinical Aspects of Ischemia With No Obstructive Coronary Artery Disease (INOCA)." American Heart Journal Plus 37 (2024): 100352. https://doi.org/10.1016/j.ahjo.2023.100352

Who We Serve

PatientsProvidersEmployers

Our Solutions

OverviewEpi+Gen CHD™PrecisionCHD™HeartRisk™CardioInnovate360™

Company

About UsAbout CVDCareersTechnologyResourcesContact Us

Investors

Stock InformationSEC FilingsPress ReleasesPresentationsEmail SubscriptionCorporate GovernanceContact Investor Relations
Contact Us

2026 Cardio Diagnostics, Inc.

Privacy PolicyTerms of UseHIPAA Notice

The Cardio Diagnostics clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing. The Epi+Gen CHD™ and PrecisionCHD™ tests were developed, and their performance characteristics were determined by Cardio Diagnostics. These tests should be ordered by a licensed healthcare provider, and test results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms, and other relevant clinical information. These tests are intended for clinical purposes and have not been cleared or approved by the U.S. Food and Drug Administration (FDA).

For the Epi+Gen CHD™ test, a lower risk result does not eliminate the possibility of a coronary heart disease event occurring or that coronary heart disease is present, and a higher risk result does not imply a diagnosis of coronary heart disease or that a coronary heart disease event will occur. For the PrecisionCHD™ test, a "Signal Detected" result is not a diagnosis of coronary heart disease, and a "Signal Not Detected" result does not eliminate the possibility that coronary heart disease is present or could occur in the future. False positive and false negative test results do occur. Rx only.

In addition to a federal CLIA license, the Cardio Diagnostics clinical laboratory holds active state clinical laboratory licenses in California, Maryland, Pennsylvania, and Rhode Island. The laboratory is not currently licensed to process patient samples originating from the state of New York.